The following message was updated on 9/22/2022 10:53:10 PM.
CC:an immunotherapy for cancer-optimistically, might be more than one immunotherapy..
Positive Funds Use Results on a tight budget
Yes. This is a follow-up. Dr. Rosol, can you just provide any more color or
depth on the 2 oncology-related preclinical trials ongoing that you're
currently planning 2024 or earlier INDs? One is the M1, M2 and -- can you
provide any more color on those?
Michael Rosol (Executives)
Sure. What we're doing is we're doing -- right now, we're doing preclinical
studies to select our lead candidate to move first towards IND for
first-in-human studies. And so you've heard me mention the various new
payloads, new constructs. We have the Dox-Manocept construct that has some
promising preliminary results.
There are reasons to believe that some of our other newer therapeutic payload
constructs will have -- would have and will have superior efficacy. And so
we've been advancing those as well preclinically. And we're getting very close
to a phase where we can say, "This is our lead and these are our other
candidates that we will also continue to advance behind those."
So things are moving. We'll be looking to do some investigator-initiated
studies to help us advance towards IND and possibly investigator-initiated IND.
So we'll work closely with research collaborators at well-known institutions
who can help us get these into humans more rapidly and do those first human
studies rapidly as well.
when that slide was crafted, it was really about taking an anti -- an
immunotherapy for cancer to IND as well as an anti-inflammatory. And at the end
of the day, optimistically, it might be more than one immunotherapy, give or
take a year between the 2,